Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.0K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.0K
Structure and Function of Platelets01:18

Structure and Function of Platelets

4.1K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glenzocimab Efficacy and Safety Added to Intravenous Thrombolysis With or Without Mechanical Thrombectomy in Patients With Acute Ischemic Stroke-ACTISAVE: A Prospective, Randomized, Double-Blind Study.

Stroke·2026
Same author

Neutrophil extracellular traps-targeting therapy with deoxyribonuclease 1 reduces large vessel occlusion-induced downstream microvascular thromboinflammation in a rat model of stroke.

Research and practice in thrombosis and haemostasis·2025
Same author

Glycoprotein VI inhibitors: glenzocimab and EMA601 two inhibitory Fabs.

European heart journal·2025
Same author

Comparative Effects of Glenzocimab and Eptifibatide on Bleeding Severity in 2 Mouse Models of Intracranial Hemorrhage.

Journal of the American Heart Association·2025
Same author

Targeting GPVI with glenzocimab in COVID-19 patients: Results from a randomized clinical trial.

PloS one·2024
Same author

Platelets favor the outgrowth of established metastases.

Nature communications·2024

Related Experiment Video

Updated: Feb 28, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K

Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function

Kristell Lebozec1, Martine Jandrot-Perrus1,2, Gilles Avenard1

  • 1a Acticor Biotech SAS, Hôpital Bichat - Inserm U1148 , 46 rue Henri Huchard, F75018 Paris , France.

Mabs
|June 10, 2017
PubMed
Summary

A novel humanized antibody fragment, ACT017, effectively inhibits collagen-induced platelet aggregation. This new anti-thrombotic drug candidate shows promise for safe and efficient treatment of arterial thrombosis without adverse effects.

Keywords:
Cardiovascular diseaseglycoprotein VIhumanizationplatelet aggregationstroketherapeutic antibodythrombosis

More Related Videos

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

12.3K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.3K

Related Experiment Videos

Last Updated: Feb 28, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K
Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

12.3K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.3K

Area of Science:

  • Pharmacology
  • Immunology
  • Hematology

Background:

  • Glycoprotein VI (GPVI) is a key platelet receptor mediating arterial thrombosis.
  • Targeting GPVI offers a potential strategy for anti-thrombotic therapy with reduced bleeding risks compared to conventional agents.

Purpose of the Study:

  • To identify and characterize a novel humanized antibody fragment, ACT017, targeting GPVI.
  • To evaluate the in vitro and ex vivo efficacy and safety of ACT017 as an anti-thrombotic agent.

Main Methods:

  • Selection of humanized Fab fragments based on structural and functional properties.
  • GMP-like production and physico-chemical characterization of ACT017.
  • In vitro and ex vivo assessment of ACT017's inhibition of collagen-induced platelet aggregation in macaques.

Main Results:

  • ACT017 demonstrated high specificity and affinity for its antigen.
  • Ex vivo studies in macaques showed ACT017 effectively inhibited collagen-induced platelet aggregation in a dose-dependent manner.
  • No thrombocytopenia, GPVI depletion, or bleeding side effects were observed with ACT017 treatment.

Conclusions:

  • ACT017 is a potent and specific inhibitor of GPVI-mediated platelet aggregation.
  • ACT017 represents a promising therapeutic candidate for a new generation of safe and effective anti-thrombotic drugs.